Amyris (NASDAQ:AMRS) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
Several other equities research analysts have also commented on the stock. Zacks Investment Research lowered shares of Amyris from a “buy” rating to a “hold” rating in a research report on Monday, October 23rd. HC Wainwright set a $15.00 price target on shares of Amyris and gave the company a “buy” rating in a research report on Wednesday. Finally, Cowen set a $4.00 price target on shares of Amyris and gave the company a “hold” rating in a research report on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Amyris has a consensus rating of “Hold” and a consensus price target of $20.69.
Shares of Amyris (NASDAQ AMRS) traded down $0.05 during trading hours on Friday, reaching $3.58. The company’s stock had a trading volume of 213,705 shares, compared to its average volume of 296,622. Amyris has a fifty-two week low of $1.86 and a fifty-two week high of $13.05. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in shares of Amyris by 16.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 4,603 shares during the last quarter. KBC Group NV increased its position in shares of Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares during the last quarter. Carl Domino Inc purchased a new stake in shares of Amyris during the 3rd quarter valued at about $182,000. Finally, Tanaka Capital Management Inc. increased its position in shares of Amyris by 72.0% during the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 221,295 shares during the last quarter. 26.06% of the stock is owned by hedge funds and other institutional investors.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
What are top analysts saying about Amyris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc. and related companies.